Viatris (WBO:MYL) Land And Improvements : €105 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Viatris Land And Improvements?

Viatris's land and improvements for the quarter that ended in Mar. 2024 was €105 Mil.

Viatris's quarterly land and improvements declined from Sep. 2023 (€116 Mil) to Dec. 2023 (€110 Mil) and declined from Dec. 2023 (€110 Mil) to Mar. 2024 (€105 Mil).

Viatris's annual land and improvements increased from Dec. 2021 (€122 Mil) to Dec. 2022 (€126 Mil) but then declined from Dec. 2022 (€126 Mil) to Dec. 2023 (€110 Mil).

Viatris Land And Improvements Historical Data

The historical data trend for Viatris's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Land And Improvements Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

Get a 7-Day Free Trial

112.14

128.07

122.04

125.93

110.22

Viatris Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Land And Improvements	Get a 7-Day Free Trial															126.09	115.47	115.72	110.22	105.43

Viatris Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Viatris (WBO:MYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (WBO:MYL) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (WBO:MYL) Headlines

No Headlines